ARCHIVES

Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase

This article is from The Cancer Letter archive.

Vol. 33 No. 12 | December 31, 2010

Download PDF Visit The Full Archive

Related Articles

NCI CTEP Approved Trials For the Month of April

April 25, 2014

Reports of SPOREs cut Premature, Broder Says, Wait for Peer Review

March 13, 1992

NCI Plans $38 Million For New Research In Tobacco Control Over Next Two Years

October 16, 1998

Review Of DCCR Programs Uncovers Problems, Assigns Scores To Each

June 30, 1978

NIEHS Director Olden Outlines Strategy For Carcinogenicity Testing

September 11, 1992

NCAB Meeting Notes: 2015 Goal Not Mentioned As NCI Faces Life After Andy. Capitol Hill: Committee Alleges Inadequate Oversight of NIH Tissue Banks.

June 16, 2006